PuraPharm Corporation Limited
1498.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$129.48M
Close$
Share Statistics
| Market cap | $129.48 Million |
|---|---|
| Enterprise Value | $487.87 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.08 |
| Beta | 0.2 |
| Outstanding Shares | 535,053,312 |
Return
| Return on Equity | -53.37% |
|---|---|
| Return on Assets | -9.46% |
| Return on Invested Capital | -15.17% |
Valuation & Multiples
| P/E Ratio | -4.25 |
|---|---|
| PEG | 12.26 |
| Price to Sales | 0.24 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.73 |
| Enterprise Value to EBIT | -14.26 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.76 |
| Debt to Equity | 2.99 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 26, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About PuraPharm Corporation Limited
460 employees
CEO: Yu Ling Chan PuraPharm Corporation Limited, an investment holding entity, focuses on the research, development, manufacturing, and global distribution of concentrated Chinese medicine granules (CCMG) and various Chinese healthcare products across Hon...